Aaron S Kesselheim1, Macarius Donneyong1, Gerald J Dal Pan2, Esther H Zhou2, Jerry Avorn1, Sebastian Schneeweiss1, John D Seeger1. 1. Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 2. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Office of Surveillance and Epidemiology (OSE), Boston, MA, USA.
Abstract
PURPOSE: Products containing the sedative/hypnotic zolpidem were subject to Drug Safety Communications (DSCs) in January and May 2013 describing the risk of next-morning impairment and recommending lower starting doses particularly for women. This study aimed to assess whether zolpidem DSCs were associated with prescribing-pattern changes between January 2011 and December 2013. METHODS: We assessed overall dispensings of zolpidem-containing products between January 2011 and December 2013 by conducting a time-series analysis. Analyses were stratified by gender because the DSC contained gender-specific information. Participants were patients drawn from the Optum Clinformatics data source of commercially insured people in the USA. We evaluated changes in mean prescribed dose of the two drugs and health care utilization metrics. RESULTS: Each month of the study, more than 80 000 patients received a zolpidem-containing product and approximately one-tenth as many received eszopiclone. The two DSCs did not affect the downward trajectory of new zolpidem prescriptions. However, there was an increase in use of lower-dose forms of zolpidem (30% increase, p < 0.001), coupled with a reduction in higher-dose forms (13% decrease, p = 0.03), so that the average dose decreased after the DSCs (from 9.7 mg to 9.4 mg, p < 0.001), a change that was not seen with eszopiclone (from 2.74 mg to 2.74 mg, p = 0.45). CONCLUSION: The DSCs related to zolpidem-containing products shifted prescribing toward the lower-dose formulations, consistent with the recommendations in the DSCs.
PURPOSE: Products containing the sedative/hypnotic zolpidem were subject to Drug Safety Communications (DSCs) in January and May 2013 describing the risk of next-morning impairment and recommending lower starting doses particularly for women. This study aimed to assess whether zolpidem DSCs were associated with prescribing-pattern changes between January 2011 and December 2013. METHODS: We assessed overall dispensings of zolpidem-containing products between January 2011 and December 2013 by conducting a time-series analysis. Analyses were stratified by gender because the DSC contained gender-specific information. Participants were patients drawn from the Optum Clinformatics data source of commercially insured people in the USA. We evaluated changes in mean prescribed dose of the two drugs and health care utilization metrics. RESULTS: Each month of the study, more than 80 000 patients received a zolpidem-containing product and approximately one-tenth as many received eszopiclone. The two DSCs did not affect the downward trajectory of new zolpidem prescriptions. However, there was an increase in use of lower-dose forms of zolpidem (30% increase, p < 0.001), coupled with a reduction in higher-dose forms (13% decrease, p = 0.03), so that the average dose decreased after the DSCs (from 9.7 mg to 9.4 mg, p < 0.001), a change that was not seen with eszopiclone (from 2.74 mg to 2.74 mg, p = 0.45). CONCLUSION: The DSCs related to zolpidem-containing products shifted prescribing toward the lower-dose formulations, consistent with the recommendations in the DSCs.
Authors: Aaron S Kesselheim; Michael S Sinha; Eric G Campbell; Sebastian Schneeweiss; Paula Rausch; Brian M Lappin; Esther H Zhou; Jerry Avorn; Gerald J Dal Pan Journal: Drug Saf Date: 2019-11 Impact factor: 5.606
Authors: Andrew I Geller; Esther H Zhou; Daniel S Budnitz; Maribeth C Lovegrove; Gerald J Dal Pan Journal: Pharmacoepidemiol Drug Saf Date: 2020-01-09 Impact factor: 2.890
Authors: Hyungjin Myra Kim; Lauren B Gerlach; Matheos Yosef; Claire Stano; Deirdre A Conroy; Marcia Valenstein; Paul N Pfeiffer; Anne E Sales; Kara Zivin Journal: J Clin Sleep Med Date: 2018-07-15 Impact factor: 4.062
Authors: Bo-Ram Yang; Kyu-Nam Heo; Yun Mi Yu; Ga-Bin Yeom; Hye Duck Choi; Ju-Yeun Lee; Young-Mi Ah Journal: Int J Environ Res Public Health Date: 2021-05-12 Impact factor: 3.390
Authors: Esther de Vries; Petra Denig; Sieta T de Vries; Taco B M Monster; Jacqueline G Hugtenburg; Peter G M Mol Journal: Drug Saf Date: 2020-07 Impact factor: 5.606